An Open-Label Trial of Sibutramine in Obese Patients With Binge-Eating Disorder

Appolinário, José Carlos; Godoy-Matos, Amélio F.; Fontenelle, Leonardo F.; Carraro, Lucia; Cabral, Mônica Dias; Vieira, A.E.D.; Coutinho, Walmir

doi:10.4088/jcp.v63n0106

Cited by 53 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The other three drugs tested (topiramate, sibutramine, and fluoxetine) have been reported to reduce binge eating in humans McElroy et al 2007;De Bernardi et al 2005;Appolinario et al 2002 Leombruni et al 2008;Shapiro et al 2007;Arnold et al 2002;Carter et al 2003; National Institute for Clinical Excellence 2004), even though only fluoxetine has been accepted by the FDA to treat the symptomatology in bulimia nervosa. Therefore, the three drugs were tested to assess the predictive validity of the experimental model.…”

Section: Vehiclementioning

confidence: 99%

“…They were chosen since clinical studies have reported that they may be effective in the treatment of bingeing-related eating disorders McElroy et al 2007;De Bernardi et al 2005;Appolinario et al 2002;Appolinario et al 2004;Milano et al 2005;Wilfley et al 2008;Leombruni et al 2008;Shapiro et al 2007;Arnold et al 2002;Carter et al 2003;National Institute for Clinical Excellence 2004). Sibutramine (Reductil®) is a centrally acting serotonin-noradrenaline reuptake inhibitor.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A preclinical model of binge eating elicited by yo-yo dieting and stressful exposure to food: effect of sibutramine, fluoxetine, topiramate, and midazolam

et al. 2009

View full text Add to dashboard Cite

show abstract

Section: Vehiclementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A preclinical model of binge eating elicited by yo-yo dieting and stressful exposure to food: effect of sibutramine, fluoxetine, topiramate, and midazolam

et al. 2009

View full text Add to dashboard Cite

show abstract

“…A recent trial of topiramate reduced binge eating from 3.4 binges per week to 0.3 binges per week, with a 5.9 kg weight loss for those on topiramate versus a 1.2 kg weight loss for those on placebo (McElroy et al, 2002). In their open-label study, Appolinario et al (2002) reported that the appetite suppressant sibutramine reduced the rate of binge eating. This development strengthens our recommendation for greater specificity in treatment.…”

Section: Psychopharmacologymentioning

confidence: 99%

Binge eating disorder: Disorder or marker?

Stunkard¹,

Allison²

2003

Int. J. Eat. Disord.

100

View full text Add to dashboard Cite

show abstract

“…Current medications, like topiramate (McElroy et al, 2007;McElroy et al, 2009) or sibutramine (Appolinario et al, 2000;Wilfley et al, 2008), have been reported to reduce BE in clinical studies. However, their administration is associated with a variety of adverse side effects, which represent serious problems during chronic treatment (McElroy et al, 2009;Carter et al, 2003;Yager, 2008).…”

Section: Introductionmentioning

confidence: 99%

Role of Orexin-1 Receptor Mechanisms on Compulsive Food Consumption in a Model of Binge Eating in Female Rats

Piccoli

Bonaventura

Cifani

et al. 2012

Neuropsychopharmacol

141

102

View full text Add to dashboard Cite

Orexins (OX) and their receptors (OXR) modulate feeding, arousal, stress, and drug abuse. Neural systems that motivate and reinforce drug abuse may also underlie compulsive food seeking and intake. Therefore, the effects of GSK1059865, a dual OX 1 /OX 2 R antagonist were evaluated in a binge eating (BE) model in female rats. BE of highly palatable food (HPF) was evoked by three cycles of food restriction followed by stress, elicited by exposing rats to HPF, but preventing them from having access to it for 15 min. Pharmacokinetic assessments of all compounds were obtained under the same experimental conditions used for the behavioral experiments. Topiramate was used as the reference compound as it selectively blocks BE in rats and humans. Dose-related thresholds for sleep-inducing effects of the OXR antagonists were measured using polysomnography in parallel experiments. SB-649868 and GSK1059865, but not JNJ-10397049, selectively reduced BE for HPF without affecting standard food pellet intake, at doses that did not induce sleep. These results indicate, for the first time, a major role of OX 1 R mechanisms in BE, suggesting that selective antagonism at OX 1 R could represent a novel pharmacological treatment for BE and possibly other eating disorders with a compulsive component.

show abstract

An Open-Label Trial of Sibutramine in Obese Patients With Binge-Eating Disorder

Cited by 53 publications

References 0 publications

A preclinical model of binge eating elicited by yo-yo dieting and stressful exposure to food: effect of sibutramine, fluoxetine, topiramate, and midazolam

A preclinical model of binge eating elicited by yo-yo dieting and stressful exposure to food: effect of sibutramine, fluoxetine, topiramate, and midazolam

Binge eating disorder: Disorder or marker?

Role of Orexin-1 Receptor Mechanisms on Compulsive Food Consumption in a Model of Binge Eating in Female Rats

Contact Info

Product

Resources

About